Clinical trial · Observational
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
A Multi-center, Retrospective, Study on Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include patient demographics, tumor characteristics, ADC regimens (e.g., trastuzumab deruxtecan, sacituzumab govitecan), treatment sequencing, survival outcomes, and safety profiles. Genomic data (e.g., HER2 expression dynamics, TROP2 levels) are integrated to explore resistance mechanisms and prognostic biomarkers.mechanisms. This study aims to investigate the efficacy of different ADC sequential regimens in HER2-low breast cancer patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Antibody-drug Conjugates | — | UNRESOLVED | — |
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| HER2-low Breast Cancer | HER2-Low Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-intervention research | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (8)
- label
- First-line Trastuzumab Deruxtecan → Second-line Sacituzumab Govitecan
- interventionNames
- Other: Non-intervention research
- label
- First-line Sacituzumab Govitecan → Second-line Trastuzumab Deruxtecan
- interventionNames
- Other: Non-intervention research
- label
- First-line RC48 → Second-line Trastuzumab Deruxtecan
- interventionNames
- Other: Non-intervention research
- label
- First-line Trastuzumab Deruxtecan → Second-line RC48
- interventionNames
- Other: Non-intervention research
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with HER2-low breast cancer, defined as immunohistochemistry (IHC) score of 1+ or IHC score of 2+ with negative in situ hybridization (FISH-negative) * Received sequential administration of two or more ADCs * Complete data for patient's character, laboratory and imaging test, treatment and follow-up are available. Exclusion Criteria: * Concomitant with other tumor components at the time of diagnosis; * Have a history of any other malignant tumors; * Lack of complete data
References
Publications (0)
Data not yet available